Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NORTH CHICAGO, ILL., SEPT. 10, 2026 /PRNEWSWIRE/ -- THE BOARD OF DIRECTORS OF ABBVIE INC. (NYSE: ABBV) TODAY DECLARED A QUARTERLY CASH DIVIDEND OF $1.73 PER SHARE.

ABBVIE DECLARES QUARTERLY DIVIDEND

MENSTRUAL MIGRAINE IS A RECURRENT, DEBILITATING MIGRAINE PATTERN, WITH ATTACKS OCCURRING AROUND OR DURING THE MENSTRUAL PERIOD, A PREDICTABLE TIME OF INCREASED BIOLOGICAL VULNERABILITY2,4 ATOGEPANT DEMONSTRATED STATISTICALLY SIGNIFICANT REDUCTIONS IN MIGRAINE DAYS ASSOCIATED WITH THE MENSTRUAL PERIOD, MEETING THE PRIMARY AND ALL EIGHT RANKED SECONDARY ENDPOINTS VERSUS PLACEBO IN THE PHASE 3 LUNA STUDY (P

ABBVIE EXTENDS MIGRAINE LEADERSHIP WITH POSITIVE PHASE 3 ATOGEPANT RESULTS IN MENSTRUAL MIGRAINE

ETENTAMIG, AN INVESTIGATIONAL ASSET, ACHIEVED A SIGNIFICANTLY IMPROVED OBJECTIVE RESPONSE RATE (ORR, 74%) AND A 60% RISK REDUCTION IN DISEASE PROGRESSION OR DEATH (PROGRESSION-FREE SURVIVAL, HAZARD RATIO 0.40) VERSUS INVESTIGATOR'S CHOICE OF STANDARD AVAILABLE THERAPIES ETENTAMIG DEMONSTRATED LOW RATES OF CYTOKINE RELEASE SYNDROME (CRS) AND FATAL INFECTIONS WITH MONTHLY DOSING (Q4W) FROM INITIATION FOLLOWING A SINGLE STEP-UP DOSE ETENTAMIG'S DOSING SCHEDULE AND CLINICAL PROFILE MAY OFFER A DIFFERENTIATED TREATMENT OPTION FOR PATIENTS AND PROVIDERS RESULTS SUPPORT THE POTENTIAL OF ETENTAMIG, A SECOND-GENERATION BCMA-DIRECTED T-CELL ENGAGER, TO ENABLE TREATMENT ACROSS A RANGE OF SETTINGS, INCLUDING OUTPATIENT AND COMMUNITY-BASED CARE NORTH CHICAGO, ILL., SEPT. 3, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) ANNOUNCED POSITIVETOPLINE RESULTS FROM THE PHASE 3 CERVINO STUDY1EVALUATING ETENTAMIG, AN INVESTIGATIONAL BCMA X CD3 BISPECIFIC T-CELL ENGAGER, VERSUS STANDARD AVAILABLE THERAPIES (SAT) IN PATIENTS WITH TRIPLE-CLASS EXPOSED (PROTEASOME INHIBITOR, IMMUNOMODULATORY DRUG AND ANTI-CD38 MONOCLONAL ANTIBODY) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE 3 CERVINO TRIAL SHOWING ETENTAMIG SIGNIFICANTLY IMPROVED RESPONSE RATE AND PROGRESSION-FREE SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

ACQUISITION DEEPENS ABBVIE'S ROBUST IMMUNOLOGY PIPELINE WITH DIVERSE ASSETS TARGETING DERMATOLOGIC, RESPIRATORY AND OTHER INFLAMMATORY AND IMMUNOLOGICAL DISEASES APOGEE'S LEAD ASSET, ZUMILOKIBART, IS A LATE-STAGE, HALF-LIFE EXTENDED MONOCLONAL ANTIBODY TARGETING IL-13, IN DEVELOPMENT FOR PATIENTS WITH ATOPIC DERMATITIS APOGEE'S PIPELINE ALSO INCLUDES APG273, A POTENTIAL BEST-IN-CATEGORY LONG-ACTING COMBINATION TARGETING IL-13 AND THYMIC STROMAL LYMPHOPOIETIN (TSLP), IN DEVELOPMENT FOR ASTHMA ABBVIE REAFFIRMS PREVIOUSLY ISSUED 2026 FULL-YEAR ADJUSTED DILUTED EPS GUIDANCE RANGE OF $13.87 - $14.07; REAFFIRMS PREVIOUSLY ISSUED THIRD-QUARTER ADJUSTED DILUTED EPS GUIDANCE RANGE OF $3.84 - $3.88 NORTH CHICAGO, ILL., SEPT. 3, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT IT HAS COMPLETED ITS ACQUISITION OF APOGEE THERAPEUTICS, INC. (NASDAQ: APGE).

ABBVIE COMPLETES ACQUISITION OF APOGEE THERAPEUTICS

NORTH CHICAGO, ILL., SEPT. 3, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) WILL PARTICIPATE IN THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, SEPTEMBER 15, 2026.

ABBVIE TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

IN CLINICAL TESTING, BARRIER CALMING CREAM IMPROVED SKIN BARRIER SUPPORT AND REDUCED SKIN DRYNESS BY 30% AFTER JUST TWO WEEKS 1 SKINMEDICA  ALSO INTRODUCES HA 5 HYDRA COLLAGEN FACIAL MIST FOR EASY, ON-THE-GO HYDRATION IRVINE, CALIF., SEPT. 1, 2026 /PRNEWSWIRE/ -- ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE:ABBV), EXPANDS SKINMEDICA'S PORTFOLIO OF REGENERATIVE SKINCARE PRODUCTS WITH THE LAUNCH OF BARRIER CALMING CREAM.

SKINMEDICA ADDS BARRIER CALMING CREAM TO ITS COLLECTION OF REGENERATIVE SKINCARE OFFERINGS

NORTH CHICAGO, ILL., AUG. 31, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) WILL PARTICIPATE IN THE WELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE ON WEDNESDAY, SEPTEMBER 9, 2026.

ABBVIE TO PRESENT AT THE WELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE

SUBMISSION SUPPORTED BY DATA FROM PHASE 3 PIVOTAL AFFIRM STUDY IF APPROVED, ADULT CROHN'S DISEASE PATIENTS WILL HAVE AN ADDITIONAL OPTION FOR INDUCTION OF RISANKIZUMAB WHICH IS ALREADY APPROVED FOR INTRAVENOUS (IV) INDUCTION NORTH CHICAGO, ILL., AUG. 27, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT IT HAS SUBMITTED AN APPLICATION TO THE EUROPEAN MEDICINES AGENCY (EMA)SEEKING APPROVAL FOR SKYRIZI(RISANKIZUMAB) FOR SUBCUTANEOUS (SC) INDUCTION FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (CD).

ABBVIE SUBMITS REGULATORY APPLICATION TO EMA FOR SKYRIZI (RISANKIZUMAB) SUBCUTANEOUS INDUCTION FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

CLINICAL DATA FROM ABBVIE'S ABBV-1480 (RC148) PD-1/VEGF BISPECIFIC ANTIBODY IN THE FRONTLINE NON-SMALL CELL LUNG CANCER (NSCLC) SETTING WILL BE PRESENTED VIA AN ORAL PRESENTATION ADDITIONALLY, NEW DATA AND UPDATES FROM ABBVIE'S TELISOTUZUMAB ADIZUTECAN (TEMAB-A) AND ABBV-706 PROGRAMS ACROSS NSCLC AND SMALL CELL LUNG CANCER(SCLC) TO BE SHARED RESEARCH REFLECTS ABBVIE'S STRATEGY AIMED AT BUILDING A LUNG CANCER PIPELINE SPANNING NEXT-GENERATION IMMUNOTHERAPIES, TARGETED ANTIBODY- DRUG CONJUGATES (ADCS) AND THE POTENTIAL FOR NOVEL COMBINATION APPROACHES NORTH CHICAGO, ILL., AUG. 21, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED NEW DATA HIGHLIGHTING RESEARCH PROGRAMS ACROSS ITS LUNG CANCER PORTFOLIO BEING PRESENTED AT THE 2026 WORLD CONFERENCE ON LUNG CANCER (WCLC), INCLUDING NON-SMALL CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG CANCER (SCLC).

ABBVIE TO PRESENT NEW DATA AT WCLC 2026 SHOWCASING INNOVATION ACROSS LUNG CANCER PIPELINE

SINCE ITS 2016 LAUNCH, HUNDREDS OF EXCEPTIONAL STUDENTS PURSUING HIGHER EDUCATION HAVE RECEIVED THE SCHOLARSHIP NOW A RENEWABLE AWARD, STUDENTS MAY EARN THE ABBVIE IMMUNOLOGY SCHOLARSHIP FOR UP TO FOUR YEARS RECIPIENTS LIVE WITH CONDITIONS SUCH AS ATOPIC DERMATITIS, PSORIASIS, CROHN'S DISEASE, ULCERATIVE COLITIS AND JUVENILE IDIOPATHIC ARTHRITIS NORTH CHICAGO, ILL., AUG. 18, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED 34 STUDENTS LIVING WITH INFLAMMATORY CONDITIONS ACROSS DERMATOLOGY, GASTROENTEROLOGY AND RHEUMATOLOGY WILL RECEIVE THE 2026 ABBVIE IMMUNOLOGY SCHOLARSHIP, AS THE PROGRAM MARKS ITS 10TH YEAR.

ABBVIE ANNOUNCES 2026 ABBVIE IMMUNOLOGY SCHOLARSHIP RECIPIENTS, CELEBRATING 10 YEARS OF SUPPORT

IF APPROVED, BOTOX  COSMETIC (ONABOTULINUMTOXINA) WOULD BE THE ONLY NEUROTOXIN WITH FIVE AESTHETIC INDICATIONS AND THE FIRST AND ONLY APPROVED FOR MASSETER MUSCLE PROMINENCE IN THE U.S. SUBMISSION IS SUPPORTED BY TWO PHASE 3 STUDIES (M21-416 AND M21-417), DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENTS IN MASSETER MUSCLE PROMINENCE AND PATIENT SATISFACTION WITH TREATMENT IRVINE, CALIF., AUG. 4, 2026 /PRNEWSWIRE/ -- ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED FOR REVIEW ITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR BOTOXCOSMETIC (ONABOTULINUMTOXINA) FOR THE TEMPORARY IMPROVEMENT IN THE APPEARANCE OF MARKED TO VERY MARKED MASSETER MUSCLE PROMINENCE (MMP) ASSOCIATED WITH MASSETER MUSCLE ACTIVITY IN ADULTS.

ALLERGAN AESTHETICS ANNOUNCES U.S. FDA ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR BOTOX COSMETIC FOR MASSETER MUSCLE PROMINENCE

REPORTS SECOND-QUARTER DILUTED EPS OF $2.03 ON A GAAP BASIS, AN INCREASE OF 290.4 PERCENT; ADJUSTED DILUTED EPS OF $3.65, AN INCREASE OF 22.9 PERCENT; THESE RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $0.17 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE DELIVERS SECOND-QUARTER NET REVENUES OF $16.990 BILLION, AN INCREASE OF 10.2 PERCENT ON A REPORTED BASIS OR 9.5 PERCENT ON AN OPERATIONAL BASIS SECOND-QUARTER GLOBAL NET REVENUES FROM THE IMMUNOLOGY PORTFOLIO WERE $8.786 BILLION, AN INCREASE OF 15.1 PERCENT ON A REPORTED BASIS, OR 14.6 PERCENT ON AN OPERATIONAL BASIS; GLOBAL SKYRIZI NET REVENUES WERE $5.505 BILLION; GLOBAL RINVOQ NET REVENUES WERE $2.525 BILLION; GLOBAL HUMIRA NET REVENUES WERE $756 MILLION SECOND-QUARTER GLOBAL NET REVENUES FROM THE NEUROSCIENCE PORTFOLIO WERE $3.228 BILLION, AN INCREASE OF 20.3 PERCENT ON A REPORTED BASIS, OR 19.8 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VRAYLAR NET REVENUES WERE $1.071 BILLION; GLOBAL BOTOX THERAPEUTIC NET REVENUES WERE $1.042 BILLION; COMBINED GLOBAL UBRELVY AND QULIPTA NET REVENUES WERE $742 MILLION; GLOBAL VYALEV NET REVENUES WERE $256 MILLION SECOND-QUARTER GLOBAL NET REVENUES FROM THE ONCOLOGY PORTFOLIO WERE $1.650 BILLION, A DECREASE OF 1.5 PERCENT ON A REPORTED BASIS, OR 2.4 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VENCLEXTA NET REVENUES WERE $771 MILLION; GLOBAL IMBRUVICA NET REVENUES WERE $532 MILLION; GLOBAL ELAHERE NET REVENUES WERE $211 MILLION SECOND-QUARTER GLOBAL NET REVENUES FROM THE AESTHETICS PORTFOLIO WERE $1.282 BILLION, AN INCREASE OF 0.3 PERCENT ON A REPORTED BASIS, OR A DECREASE OF 0.9 PERCENT ON AN OPERATIONAL BASIS; GLOBAL BOTOX COSMETIC NET REVENUES WERE $728 MILLION; GLOBAL JUVEDERM NET REVENUES WERE $245 MILLION ANNOUNCED DEFINITIVE AGREEMENT TO ACQUIRE APOGEE THERAPEUTICS, DEEPENING ABBVIE'S IMMUNOLOGY PORTFOLIO UPDATES 2026 ADJUSTED DILUTED EPS GUIDANCE RANGE FROM $13.91 - $14.11 TO $13.87 - $14.07; NOW INCLUDES A $0.14 PER SHARE DILUTIVE IMPACT RELATED TO THE PROPOSED ACQUISIT

ABBVIE REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF APOGEE THERAPEUTICS, INC. (NASDAQGM: APGE) TO ABBVIE (NYSE: ABBV). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF APOGEE WILL RECEIVE $135.11 IN CASH FOR EACH SHARE OF APOGEE THAT THEY OWN. KSF IS SEEKING TO DETERMINE WHETHER THIS CONSIDERATION AND THE PROCESS THAT LED TO IT ARE A.

APOGEE THERAPEUTICS INVESTOR ALERT: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF APOGEE THERAPEUTICS, INC. - APGE

ALLERGAN AESTHETICS CELEBRATES FOURTH ANNUAL JUVDERM  DAY WITH BUY-ONE-GET-ONE (BOGO) GIFT CARDS AND DOUBLE POINTS FOR ALL MEMBERS THIS SUMMER MARKS THE 20TH ANNIVERSARY OF THE BRAND'S FIRST U.S. FOOD AND DRUG ADMINISTRATION (FDA) DERMAL FILLER APPROVAL JOIN ALL TODAY TO TAKE ADVANTAGE OF LIMITED TIME OFFERS, WHILE SUPPLIES LAST NORTH CHICAGO, ILL., JULY 30, 2026 /PRNEWSWIRE/ -- ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), TODAY ANNOUNCED THE RETURN OF JUVDERMDAYON WEDNESDAY, AUGUST 19, 2026, WITH EXCLUSIVE JUVDERMOFFERS FOR ALLMEMBERS.

JUVDERM DAY RETURNS TO U.S. ON AUGUST 19

RINVOQ IS THE FIRST AND ONLY SYSTEMIC MEDICATION APPROVED IN THE EUROPEAN UNION TO TREAT ADULT AND ADOLESCENT PATIENTS WITH NON-SEGMENTAL VITILIGO (NSV) THE APPROVAL IS SUPPORTED BY DATA FROM THE PHASE 3 VITI-UP CLINICAL PROGRAM, WHICH SHOWED THAT RINVOQ ACHIEVED STATISTICALLY SIGNIFICANT TOTAL BODY (T-VASI 50) AND FACIAL REPIGMENTATION (F-VASI 75) FROM BASELINE AT WEEK 48, VERSUS PLACEBO 1 NORTH CHICAGO, ILL., JULY 29, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS APPROVED RINVOQ(UPADACITINIB; 15 MG, ONCE DAILY) FOR THE TREATMENT OF ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH NON-SEGMENTAL VITILIGO (NSV) WHO ARE CANDIDATES FOR SYSTEMIC THERAPY.1WITH THIS APPROVAL, RINVOQ IS NOW THE FIRST AND ONLY SYSTEMIC MEDICATION APPROVED IN THE EUROPEAN UNION FOR NSV, THE MOST COMMON FORM OF VITILIGO.2 "THE EUROPEAN COMMISSION'S APPROVAL OF RINVOQ AS THE FIRST AND ONLY SYSTEMIC TREATMENT FOR NON-SEGMENTAL VITILIGO IS AN ADVANCEMENT FOR PATIENTS LIVING WITH THIS CHRONIC AUTOIMMUNE DISEASE," SAID ROOPAL THAKKAR, M.D.

ABBVIE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF RINVOQ (UPADACITINIB) FOR THE TREATMENT OF ADULTS AND ADOLESCENTS WITH NON-SEGMENTAL VITILIGO

RINVOQ  IS NOW APPROVED IN THE EUROPEAN UNION FOR THE TREATMENT OF ADULT AND ADOLESCENT PATIENTS WITH SEVERE ALOPECIA AREATA (AA) APPROVAL WAS BASED ON THE PIVOTAL PHASE 3 UP-AA CLINICAL PROGRAM, WHICH SHOWED THAT RINVOQ ACHIEVED STATISTICALLY SIGNIFICANT SCALP HAIR REGROWTH (SEVERITY OF ALOPECIA TOOL (SALT) SCORE  20) AND IMPROVEMENTS IN EYEBROWS AND EYELASHES AT WEEK 24 1 RINVOQ IS THE FIRST JAK INHIBITOR TO ACHIEVE COMPLETE SCALP HAIR REGROWTH (SALT = 0) VERSUS PLACEBO AT WEEK 24 NORTH CHICAGO, ILL., JULY 29, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS APPROVED RINVOQ(UPADACITINIB; 15 MG AND 30 MG, ONCE DAILY) FOR THE TREATMENT OF ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH SEVERE ALOPECIA AREATA (AA).1 "THE EUROPEAN COMMISSION'S APPROVAL OF RINVOQ PROVIDES A NEW TREATMENT OPTION FOR THE SEVERE ALOPECIA AREATA COMMUNITY IN THE EU WITH DEMONSTRATED SCALP REGROWTH, INCLUDING COMPLETE SCALP HAIR REGROWTH FOR SOME, THAT CAN SUPPORT MANAGEMENT OF THE DISEASE," SAID ROOPAL THAKKAR, M.D.

ABBVIE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF RINVOQ (UPADACITINIB) FOR THE TREATMENT OF ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA

COPENHAGEN, DENMARK & NORTH CHICAGO, ILL.--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) AND ABBVIE (NYSE: ABBV) TODAY PROVIDED CLARIFICATION ON THE PRIMARY ENDPOINTS FROM THE PHASE 3 EPCORE DLBCL-1 STUDY EVALUATING MONOTHERAPY EPCORITAMAB (DUOBODY-CD3XCD20), A T-CELL ENGAGING BISPECIFIC ANTIBODY ADMINISTERED SUBCUTANEOUSLY, COMPARED WITH INVESTIGATOR'S CHOICE OF CHEMOIMMUNOTHERAPY (CIT) OF EITHER RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN ADULTS.

GENMAB AND ABBVIE PROVIDE CLARIFICATION ON PHASE 3 EPCORE DLBCL-1 TRIAL EVALUATING EPCORITAMAB (DUOBODY-CD3XCD20) IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

BOEY IS THE FIRST AND ONLY RAPID-ONSET AND SHORT-DURATION BOTULINUM NEUROTOXIN SEROTYPE E APPROVED IN EUROPE THAT ADULT PATIENTS CAN TRY FOR THE TEMPORARY IMPROVEMENT OF GLABELLAR LINES RESULTS MAY BE SEEN AS EARLY AS EIGHT HOURS AFTER TREATMENT AND TYPICALLY WEAR OFF WITHIN APPROXIMATELY TWO TO THREE WEEKS BOEY OFFERS A DIFFERENTIATED TREATMENT OPTION FOR MANY PEOPLE WHO ARE CURIOUS ABOUT FACIAL INJECTABLES NORTH CHICAGO, ILL., JULY 17, 2026 /PRNEWSWIRE/ -- ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), ANNOUNCED THE EUROPEAN COMMISSION HAS APPROVED BOEY(TRENIBOTULINUMTOXINE) IN EUROPE, FOR THE TEMPORARY IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE LINES BETWEEN THE EYEBROWS SEEN AT MAXIMUM FROWN (GLABELLAR LINES) IN ADULT PATIENTS, WHEN THESE HAVE AN IMPORTANT PSYCHOLOGICAL IMPACT.1 FOLLOWING COMPLETION OF THE CENTRALIZED PROCEDURE, THE EUROPEAN COMMISSION DECISION APPLIES ACROSS ALL 30 EUROPEAN ECONOMIC AREA (EEA) COUNTRIES.

ALLERGAN AESTHETICS RECEIVES APPROVAL FOR BOEY (TRENIBOTULINUMTOXINE), FOR USE IN EUROPE: THE FIRST AND ONLY RAPID-ONSET, SHORT-DURATION NEUROTOXIN FOR THE TEMPORARY IMPROVEMENT OF FROWN LINES IN ADULT PATIENTS

SKINMEDICA  LAUNCHES REGENERATIVE SCIENCE ADVISORY BOARD TO SHAPE FUTURE INNOVATION EXPANDS ITS STATE-OF-THE-ART RESEARCH AND DEVELOPMENT (R&D) FACILITY TO SUPPORT THE NEXT GENERATION OF SCIENCE-LED INNOVATION DEBUTS FLAGSHIP RETAIL EXPERIENCES DESIGNED TO SUPPORT PRACTICE AND PATIENTS' NEEDS IRVINE, CALIF., JULY 14, 2026 /PRNEWSWIRE/ --ALLERGAN AESTHETICS, AN ABBVIE (NYSE: ABBV) COMPANY, IS PROUD TO ANNOUNCE SKINMEDICA'S EXPANDED COMMITMENT TO REGENERATIVE SCIENCE, ADVANCING INVESTMENTS THAT WILL SUPPORT INNOVATION, RESEARCH, CLINICAL INSIGHT, AND PATIENT EXPERIENCE.

AbbVie Inc.

ABBV

Price

Financial Reports

No items found.

Press Releases

AbbVie Inc.

ABBV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ABBV